Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 12:35 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®

ClinicalTrials.gov · NCT05897398 · Registry updated: 2025-09-02

Condition / research focus: Obesity; Bariatric Surgery; Binge Eating Disorder; Syndromic Obesity; Sarcopenic Obesity; Iatrogenic Obesity; Psychotropic Drugs
Sponsor: Hospices Civils de Lyon
Countries with listed sites: France
Registry dates and results: Start: 2024-06-10. Completion: 2025-06-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Data collection (other)
Blood sampling (other)
Questionnaires (other)

Where the study takes place — 14 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Service Endocrinologie Diabétologie Nutrition APHP - Hôpital Jean Verdier
Bondy, France
Site recruitment: Not reported
Service de chirurgie APHP - GHU Nord Hôpital Louis Mourier
Colombes, France
Site recruitment: Not reported
Espace Médical Nutrition & Obésité (EMNO) Maison Médicale Valmy
Dijon, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Maladies Métaboliques CHU François Mitterrand Dijon
Dijon, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie CHU de Grenoble
La Tronche, France
Site recruitment: Not reported
Service Endocrinologie Hôpital Conception - APHM
Marseille, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Nutrition Hôpital Lapeyronie - CHU Montpellier
Montpellier, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Nutrition CHU de Nantes - Hôpital Guillaume & René Laennec
Nantes, France
Site recruitment: Not reported
Service Nutrition APHP - GHU Pitié Salpêtrière
Paris, France
Site recruitment: Not reported
Service Nutrition Diabétologie Endocrinologie APHP - Hôpital Européen Georges-Pompidou (HEGP)
Paris, France
Site recruitment: Not reported
Service Endocrinologie Hôpital Haut Léveque - CHU Bordeaux
Pessac, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Nutrition CHU Poitiers
Poitiers, France
Site recruitment: Not reported
Service Endocrinologie, Maladies Métaboliques et Nutrition Hôpital Rangueil (CHU Toulouse)
Toulouse, France
Site recruitment: Not reported
Service Endocrinologie Diabète Nutrition Hôpitaux de Brabois - CHU Nancy
Vandœuvre-lès-Nancy, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

ClinicalTrials.gov · NCT06986993 · Registry updated: 2025-08-27

Condition / research focus: Tobacco Use
Sponsor: University of Oklahoma
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-01. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic
Placebo (drug) — also listed as: Saline

Where the study takes place — 1 listed sites

Health Promotion Research Center
Oklahoma City, Oklahoma, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT07139548 · Registry updated: 2025-08-24

Condition / research focus: T2DM
Sponsor: Guangdong Raynovent Biotech Co., Ltd
Countries with listed sites: China
Registry dates and results: Start: 2025-08-31. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

RAY1225 (drug)
Semaglutide (drug)

Where the study takes place — 1 listed sites

Peking University People's Hospital
Beijing, Heibei, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effects of Semaglutide on Nicotine Intake

ClinicalTrials.gov · NCT05530577 · Registry updated: 2025-08-22

Condition / research focus: Tobacco Use Disorder; Nicotine Addiction
Sponsor: University of North Carolina, Chapel Hill
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-07. Completion: 2024-05-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
Sham/placebo (drug)

Where the study takes place — 1 listed sites

University of North Carolina
Chapel Hill, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Improved Treatment and Monitoring of Alzheimer's Disease

ClinicalTrials.gov · NCT07135245 · Registry updated: 2025-08-22

Condition / research focus: Alzheimer Disease (AD)
Sponsor: Rune Skovgaard Rasmussen
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-01-01. Completion: 2031-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Rybelsus®) combined with other interventions (drug) — also listed as: Candesartan, multivitamin-mineral tablets containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®), Combination group
Placebo (other)
Semaglutide (Rybelsus®) (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Semaglutide Treatment in Type 1 Diabetes

ClinicalTrials.gov · NCT06909006 · Registry updated: 2025-08-08

Condition / research focus: Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diabetes Mellitus
Sponsor: Nordsjaellands Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2025-10. Completion: 2028-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 2.4mg (drug) — also listed as: Active semaglutide
Semaglutide placebo (drug) — also listed as: Placebo semaglutide

Where the study takes place — 1 listed sites

Nordsjaellands Hospital
Hillerød, Denmark, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

ClinicalTrials.gov · NCT05895643 · Registry updated: 2025-08-05

Condition / research focus: Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder
Sponsor: Psychiatric Centre Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2023-06-13. Completion: 2025-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide Injectable Product (drug) — also listed as: Wegovy
Placebo (drug) — also listed as: BD Posiflush (saline)

Where the study takes place — 1 listed sites

Psychiatric Center Copenhagen, Frederiksberg Hospital
Frederiksberg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of HS-20094 in T2DM Participants

ClinicalTrials.gov · NCT06118008 · Registry updated: 2025-08-03

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-05-31. Completion: 2024-01-04 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HS-20094 5mg (drug) — also listed as: HS-20094 injection 5mg
HS-20094 10mg (drug) — also listed as: HS-20094 injection 10mg
HS-20094 15mg (drug) — also listed as: HS-20094 injection 15mg
HS-20094 20mg (drug) — also listed as: HS-20094 injection 20mg

Where the study takes place — 1 listed sites

Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

ClinicalTrials.gov · NCT06634927 · Registry updated: 2025-08-01

Condition / research focus: Type 2 Diabetes
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-09-22. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ozempic® (drug)
HDG1901 (drug)

Where the study takes place — 1 listed sites

The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

ClinicalTrials.gov · NCT07092618 · Registry updated: 2025-07-30

Condition / research focus: Longevity; GLP-1; Geroscience; Aging
Sponsor: AgelessRx
Countries with listed sites: United States
Registry dates and results: Start: 2024-12-17. Completion: 2025-08 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug)
Rapamycin (drug)
Naltrexone (drug)
Vitamin C (dietary_supplement)

Where the study takes place — 1 listed sites

AgelessRx
Chicago, Illinois, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Early Phase 1Enrolling by invitationINTERVENTIONAL

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

ClinicalTrials.gov · NCT07092605 · Registry updated: 2025-07-30

Condition / research focus: Longevity; Quality of Life; Mood; Inflammation; Immune Health; Pain Management; Weight Management; Alertness
Sponsor: AgelessRx
Countries with listed sites: United States
Registry dates and results: Start: 2024-11-01. Completion: 2025-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug) — also listed as: Semaglutide
Placebo (drug)

Where the study takes place — 1 listed sites

AgelessRx
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

ClinicalTrials.gov · NCT07090343 · Registry updated: 2025-07-29

Condition / research focus: Aortic Stenosis; Heart Failure
Sponsor: Leiden University Medical Center
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-04-01. Completion: 2031-04-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Wegovy ® (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT06739044 · Registry updated: 2025-07-28

Condition / research focus: Type 2 Diabetes
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-09-20. Completion: 2025-02-21 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ozempic® (drug)
HDG1901 (drug)

Where the study takes place — 1 listed sites

Beijing Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

ClinicalTrials.gov · NCT07073053 · Registry updated: 2025-07-18

Condition / research focus: Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
Sponsor: Taipei Veterans General Hospital, Taiwan
Countries with listed sites: Taiwan
Registry dates and results: Start: 2025-10-01. Completion: 2028-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 1.0 mg (drug)
Semaglutide 0.5 mg (drug)

Where the study takes place — 1 listed sites

Taipei Veterans General Hospital
Taipei, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT07056803 · Registry updated: 2025-07-17

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: University of Palermo
Countries with listed sites: Italy
Registry dates and results: Start: 2024-01-01. Completion: 2025-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)
subcutaneous semaglutide (drug)

Where the study takes place — 1 listed sites

Policlinico Paolo Giaccone
Palermo, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

ClinicalTrials.gov · NCT06097390 · Registry updated: 2025-07-17

Condition / research focus: Healthy Participants
Sponsor: Novo Nordisk A/S
Countries with listed sites: Canada
Registry dates and results: Start: 2023-09-28. Completion: 2024-03-27 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 1 listed sites

Altasciences Clinical Company, Inc
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

ClinicalTrials.gov · NCT04451837 · Registry updated: 2025-07-16

Condition / research focus: Type2 Diabetes
Sponsor: Region Skane
Countries with listed sites: Sweden
Registry dates and results: Start: 2020-09-10. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic
Dapagliflozin (drug) — also listed as: Forxiga

Where the study takes place — 1 listed sites

Anders Rosengrentest
Malmö, Skåne County, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT06161844 · Registry updated: 2025-07-11

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-02-23. Completion: 2025-05-14 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide injection (HD1916) (drug)
Ozempic® (drug)

Where the study takes place — 1 listed sites

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangdong, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

ClinicalTrials.gov · NCT07043361 · Registry updated: 2025-07-09

Condition / research focus: Metabolic Disease
Sponsor: Hillel Yaffe Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2023-12-18. Completion: 2025-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide (drug)

Where the study takes place — 1 listed sites

Leumit Health ccare system
Hadera, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT07046273 · Registry updated: 2025-07-01

Condition / research focus: Type 2 Diabetes (T2DM)
Sponsor: Shandong New Time Pharmaceutical Co., LTD
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-08-01. Completion: 2029-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

F027 (drug)
Ozempic® (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 12:35 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®

ClinicalTrials.gov · NCT05897398 · Registry updated: 2025-09-02

Condition / research focus: Obesity; Bariatric Surgery; Binge Eating Disorder; Syndromic Obesity; Sarcopenic Obesity; Iatrogenic Obesity; Psychotropic Drugs
Sponsor: Hospices Civils de Lyon
Countries with listed sites: France
Registry dates and results: Start: 2024-06-10. Completion: 2025-06-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Data collection (other)
Blood sampling (other)
Questionnaires (other)

Where the study takes place — 14 listed sites

Service Endocrinologie Diabétologie Nutrition APHP - Hôpital Jean Verdier
Bondy, France
Site recruitment: Not reported
Service de chirurgie APHP - GHU Nord Hôpital Louis Mourier
Colombes, France
Site recruitment: Not reported
Espace Médical Nutrition & Obésité (EMNO) Maison Médicale Valmy
Dijon, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Maladies Métaboliques CHU François Mitterrand Dijon
Dijon, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie CHU de Grenoble
La Tronche, France
Site recruitment: Not reported
Service Endocrinologie Hôpital Conception - APHM
Marseille, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Nutrition Hôpital Lapeyronie - CHU Montpellier
Montpellier, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Nutrition CHU de Nantes - Hôpital Guillaume & René Laennec
Nantes, France
Site recruitment: Not reported
Service Nutrition APHP - GHU Pitié Salpêtrière
Paris, France
Site recruitment: Not reported
Service Nutrition Diabétologie Endocrinologie APHP - Hôpital Européen Georges-Pompidou (HEGP)
Paris, France
Site recruitment: Not reported
Service Endocrinologie Hôpital Haut Léveque - CHU Bordeaux
Pessac, France
Site recruitment: Not reported
Service Endocrinologie Diabétologie Nutrition CHU Poitiers
Poitiers, France
Site recruitment: Not reported
Service Endocrinologie, Maladies Métaboliques et Nutrition Hôpital Rangueil (CHU Toulouse)
Toulouse, France
Site recruitment: Not reported
Service Endocrinologie Diabète Nutrition Hôpitaux de Brabois - CHU Nancy
Vandœuvre-lès-Nancy, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

ClinicalTrials.gov · NCT06986993 · Registry updated: 2025-08-27

Condition / research focus: Tobacco Use
Sponsor: University of Oklahoma
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-01. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic
Placebo (drug) — also listed as: Saline

Where the study takes place — 1 listed sites

Health Promotion Research Center
Oklahoma City, Oklahoma, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT07139548 · Registry updated: 2025-08-24

Condition / research focus: T2DM
Sponsor: Guangdong Raynovent Biotech Co., Ltd
Countries with listed sites: China
Registry dates and results: Start: 2025-08-31. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

RAY1225 (drug)
Semaglutide (drug)

Where the study takes place — 1 listed sites

Peking University People's Hospital
Beijing, Heibei, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effects of Semaglutide on Nicotine Intake

ClinicalTrials.gov · NCT05530577 · Registry updated: 2025-08-22

Condition / research focus: Tobacco Use Disorder; Nicotine Addiction
Sponsor: University of North Carolina, Chapel Hill
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-07. Completion: 2024-05-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
Sham/placebo (drug)

Where the study takes place — 1 listed sites

University of North Carolina
Chapel Hill, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Improved Treatment and Monitoring of Alzheimer's Disease

ClinicalTrials.gov · NCT07135245 · Registry updated: 2025-08-22

Condition / research focus: Alzheimer Disease (AD)
Sponsor: Rune Skovgaard Rasmussen
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-01-01. Completion: 2031-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (Rybelsus®) combined with other interventions (drug) — also listed as: Candesartan, multivitamin-mineral tablets containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®), Combination group
Placebo (other)
Semaglutide (Rybelsus®) (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Semaglutide Treatment in Type 1 Diabetes

ClinicalTrials.gov · NCT06909006 · Registry updated: 2025-08-08

Condition / research focus: Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diabetes Mellitus
Sponsor: Nordsjaellands Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2025-10. Completion: 2028-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 2.4mg (drug) — also listed as: Active semaglutide
Semaglutide placebo (drug) — also listed as: Placebo semaglutide

Where the study takes place — 1 listed sites

Nordsjaellands Hospital
Hillerød, Denmark, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

ClinicalTrials.gov · NCT05895643 · Registry updated: 2025-08-05

Condition / research focus: Alcohol Abuse; Alcohol Addiction; Alcohol Dependence; Alcohol Use Disorder
Sponsor: Psychiatric Centre Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2023-06-13. Completion: 2025-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide Injectable Product (drug) — also listed as: Wegovy
Placebo (drug) — also listed as: BD Posiflush (saline)

Where the study takes place — 1 listed sites

Psychiatric Center Copenhagen, Frederiksberg Hospital
Frederiksberg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of HS-20094 in T2DM Participants

ClinicalTrials.gov · NCT06118008 · Registry updated: 2025-08-03

Condition / research focus: Type 2 Diabetes
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-05-31. Completion: 2024-01-04 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HS-20094 5mg (drug) — also listed as: HS-20094 injection 5mg
HS-20094 10mg (drug) — also listed as: HS-20094 injection 10mg
HS-20094 15mg (drug) — also listed as: HS-20094 injection 15mg
HS-20094 20mg (drug) — also listed as: HS-20094 injection 20mg

Where the study takes place — 1 listed sites

Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

ClinicalTrials.gov · NCT06634927 · Registry updated: 2025-08-01

Condition / research focus: Type 2 Diabetes
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-09-22. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ozempic® (drug)
HDG1901 (drug)

Where the study takes place — 1 listed sites

The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3RecruitingINTERVENTIONAL

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

ClinicalTrials.gov · NCT07092618 · Registry updated: 2025-07-30

Condition / research focus: Longevity; GLP-1; Geroscience; Aging
Sponsor: AgelessRx
Countries with listed sites: United States
Registry dates and results: Start: 2024-12-17. Completion: 2025-08 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Metformin (drug)
Rapamycin (drug)
Naltrexone (drug)
Vitamin C (dietary_supplement)

Where the study takes place — 1 listed sites

AgelessRx
Chicago, Illinois, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Early Phase 1Enrolling by invitationINTERVENTIONAL

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

ClinicalTrials.gov · NCT07092605 · Registry updated: 2025-07-30

Condition / research focus: Longevity; Quality of Life; Mood; Inflammation; Immune Health; Pain Management; Weight Management; Alertness
Sponsor: AgelessRx
Countries with listed sites: United States
Registry dates and results: Start: 2024-11-01. Completion: 2025-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug) — also listed as: Semaglutide
Placebo (drug)

Where the study takes place — 1 listed sites

AgelessRx
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

ClinicalTrials.gov · NCT07090343 · Registry updated: 2025-07-29

Condition / research focus: Aortic Stenosis; Heart Failure
Sponsor: Leiden University Medical Center
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-04-01. Completion: 2031-04-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Wegovy ® (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT06739044 · Registry updated: 2025-07-28

Condition / research focus: Type 2 Diabetes
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-09-20. Completion: 2025-02-21 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ozempic® (drug)
HDG1901 (drug)

Where the study takes place — 1 listed sites

Beijing Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

ClinicalTrials.gov · NCT07073053 · Registry updated: 2025-07-18

Condition / research focus: Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
Sponsor: Taipei Veterans General Hospital, Taiwan
Countries with listed sites: Taiwan
Registry dates and results: Start: 2025-10-01. Completion: 2028-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 1.0 mg (drug)
Semaglutide 0.5 mg (drug)

Where the study takes place — 1 listed sites

Taipei Veterans General Hospital
Taipei, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT07056803 · Registry updated: 2025-07-17

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: University of Palermo
Countries with listed sites: Italy
Registry dates and results: Start: 2024-01-01. Completion: 2025-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)
subcutaneous semaglutide (drug)

Where the study takes place — 1 listed sites

Policlinico Paolo Giaccone
Palermo, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

ClinicalTrials.gov · NCT06097390 · Registry updated: 2025-07-17

Condition / research focus: Healthy Participants
Sponsor: Novo Nordisk A/S
Countries with listed sites: Canada
Registry dates and results: Start: 2023-09-28. Completion: 2024-03-27 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 1 listed sites

Altasciences Clinical Company, Inc
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

ClinicalTrials.gov · NCT04451837 · Registry updated: 2025-07-16

Condition / research focus: Type2 Diabetes
Sponsor: Region Skane
Countries with listed sites: Sweden
Registry dates and results: Start: 2020-09-10. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic
Dapagliflozin (drug) — also listed as: Forxiga

Where the study takes place — 1 listed sites

Anders Rosengrentest
Malmö, Skåne County, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT06161844 · Registry updated: 2025-07-11

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-02-23. Completion: 2025-05-14 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide injection (HD1916) (drug)
Ozempic® (drug)

Where the study takes place — 1 listed sites

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangdong, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

ClinicalTrials.gov · NCT07043361 · Registry updated: 2025-07-09

Condition / research focus: Metabolic Disease
Sponsor: Hillel Yaffe Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2023-12-18. Completion: 2025-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide (drug)

Where the study takes place — 1 listed sites

Leumit Health ccare system
Hadera, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT07046273 · Registry updated: 2025-07-01

Condition / research focus: Type 2 Diabetes (T2DM)
Sponsor: Shandong New Time Pharmaceutical Co., LTD
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-08-01. Completion: 2029-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

F027 (drug)
Ozempic® (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →